NDAORALCAPSULE, EXTENDED RELEASE
Approved
Feb 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
6/8 — Strong
AMRIX (cyclobenzaprine hydrochloride) by Teva is function. Approved for chronic migraine. First approved in 2007.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMRIX is an extended-release oral capsule formulation of cyclobenzaprine hydrochloride, a centrally acting skeletal muscle relaxant approved for chronic migraine. It works primarily at the brainstem to reduce tonic somatic motor activity by influencing both gamma and alpha motor systems, with pharmacological similarities to tricyclic antidepressants. The drug is indicated for chronic migraine management in patients seeking oral muscle relaxation therapy.
$0.577MPart D
LOE ApproachingDeclining
Low commercial activity with minimal linked job positions; team likely focused on managed decline and efficiency optimization as LOE approaches.
Mechanism of Action
function. Cyclobenzaprine has not been shown to be effective in muscle spasm due to central nervous system disease. In animal models, cyclobenzaprine reduced or abolished skeletal muscle hyperactivity. Animal studies indicate that cyclobenzaprine does not act at the neuromuscular junction or…
Worked on AMRIX at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.